Azilsartan as an antihypertensive treatment in Japanese children under 6 years old: A phase 3 open‐label long‐term study
Shuichi Ito, Masakazu Miyamoto, Yuki Mizuta, Kenkichi Sugiura et autres
0 citationsPediatrics International
Kenkichi Sugiura
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
27Publications signalées
503Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Inflammatory Bowel DiseaseRheumatoid Arthritis Research and TherapiesGenetic Associations and EpidemiologyPhysics of Superconductivity and MagnetismBlood Pressure and Hypertension Studies
Publications récentes
Safety, efficacy, and pharmacokinetics of icatibant treatment in Japanese pediatric patients with hereditary angioedema: A phase 3, open‐label study
Michihiro Hide, Yi Wang, Nobuhito Dote, Kou Miyakawa et autres
5 citationsThe Journal of Dermatology
Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance Study
Katsuyoshi Matsuoka, Tadakazu Hisamatsu, Yohei Mikami, Takayuki Yamamoto et autres
3 citationsAdvances in Therapy
Safety and efficacy of azilsartan in paediatric patients with hypertension: a phase 3, single-arm, open-label, prospective study
Shuichi Ito, Yuya Nishiyama, Kenkichi Sugiura, Kazuaki Enya
2 citationsClinical and Experimental Nephrology
Effects of vedolizumab in Japanese patients with Crohn’s disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses
Kenji Watanabe, Satoshi Motoya, Haruhiko Ogata, Takanori Kanai∥ et autres
57 citationsJournal of Gastroenterology
Tu1746 – A Phase 3 Study of Vedolizumab for Induction and Maintenance Therapy in Japanese Patients with Moderate to Severe Crohn's Disease
Haruhiko Ogata, Satoshi Motoya, Kenji Watanabe, Takanori Kanai∥ et autres
1 citationGastroenterology
Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study
Satoshi Motoya, Kenji Watanabe, Haruhiko Ogata, Takanori Kanai∥ et autres
13 citationsPLoS ONE
Overview of adverse events (Safety analysis set).
Satoshi Motoya (3534755), Kenji Watanabe (75040), Haruhiko Ogata, Takanori Kanai∥ et autres
0 citationsFigshare
Efficacy outcomes at weeks 10 and 60 (Induction and maintenance phases).
Satoshi Motoya (3534755), Kenji Watanabe (75040), Haruhiko Ogata, Takanori Kanai∥ et autres
0 citationsFigshare
Adverse events by preferred term with an incidence of ≥5% in any treatment group (Safety analysis set).
Satoshi Motoya (3534755), Kenji Watanabe (75040), Haruhiko Ogata, Takanori Kanai∥ et autres
0 citationsFigshare
Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study
Satoshi Motoya, Kenji Watanabe, Haruhiko Ogata, Takanori Kanai∥ et autres
103 citationsPLoS ONE
Japan PGx Data Science Consortium Database: SNPs and HLA genotype data from 2994 Japanese healthy individuals for pharmacogenomics studies
Shigeo Kamitsuji, Takashi Matsuda, Koichi Nishimura, Seiko Endo et autres
27 citationsJournal of Human Genetics
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.